Results 101 to 110 of about 23,251 (254)

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

open access: yesSmart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou   +4 more
wiley   +1 more source

Microfluidic Molecular Diagnostic Chips: Functional Modules, Integration Strategies, and Emerging Applications

open access: yesSmall Methods, EarlyView.
This comprehensive review delivers an engineering‐centric analysis of microfluidic molecular diagnostic chips, breaking them down into foundational modules from fluid manipulation to bio‐sensing. Beyond chip design, it evaluates sample‐to‐answer integration strategies and commercial readiness levels.
Donghoon Koo   +7 more
wiley   +1 more source

CD200 Expression in Folliculotropic Mycosis Fungoides Emerging During Dupilumab Treatment

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Folliculotropic mycosis fungoides (FMF) or mycosis fungoides with folliculotropism (MF‐F) is increasingly recognized in patients initially diagnosed with atopic dermatitis (AD) who subsequently worsen during dupilumab therapy. We report a case of FMF that became clinically apparent after dupilumab treatment.
Mai Tamaki   +9 more
wiley   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam   +7 more
wiley   +1 more source

Radiation therapy for persistent or progressive mediastinal lymphoma after chemotherapy in FeLV‐positive cats: a retrospective case series of four cats

open access: yesAustralian Veterinary Journal, EarlyView.
Background Mediastinal lymphoma in feline leukaemia virus (FeLV)‐positive cats is associated with a poor prognosis, and therapeutic options may be limited when adequate disease control is not achieved with chemotherapy. The efficacy of radiation therapy in this setting has not been established.
A Uno, T Hasegawa, T Mori
wiley   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia. [PDF]

open access: yesEur J Haematol
Gao L   +4 more
europepmc   +1 more source

Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest   +15 more
wiley   +1 more source

Crystal-Like Inclusions in Chronic Lymphocytic Leukaemia Lymphocytes. [PDF]

open access: yesInt J Lab Hematol
Vidal-Pla M   +3 more
europepmc   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy